MX2020004587A - Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt. - Google Patents

Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt.

Info

Publication number
MX2020004587A
MX2020004587A MX2020004587A MX2020004587A MX2020004587A MX 2020004587 A MX2020004587 A MX 2020004587A MX 2020004587 A MX2020004587 A MX 2020004587A MX 2020004587 A MX2020004587 A MX 2020004587A MX 2020004587 A MX2020004587 A MX 2020004587A
Authority
MX
Mexico
Prior art keywords
arm
anticodon
stop codons
trna
acceptor
Prior art date
Application number
MX2020004587A
Other languages
English (en)
Inventor
Christopher Ahern
John D Lueck
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2020004587A publication Critical patent/MX2020004587A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En ciertas modalidades, la presente invención proporciona un ARN de transferencia (ARNt) modificado que comprende un brazo T, un brazo D, un brazo de anticodón y un brazo aceptor, en donde el brazo T comprende nucleótidos que interaccionan con la proteína del factor de elongación 1 alfa 1, y métodos de uso del mismo. En ciertas modalidades, la presente invención provee un ARN de transferencia (ARNt) modificado que comprende un brazo T, un brazo D, un brazo anticodón y un brazo aceptor, (a) en donde el brazo anticodón comprende un anticodón trinucleotídico, en donde el anticodón es 5'-UCA-3' y reconoce codones de paro TGA, y en donde el brazo aceptor está enlazado operativamente a una arginina, triptófano o glicina; (b) en donde el brazo anticodón comprende un anticodón trinucleotídico, en donde el anticodón es 5'-UUA-3' y reconoce codones de paro TAA, y en donde el brazo aceptor está enlazado operativamente a una glutamina o glutamato; o (c) en donde el brazo anticodón comprende un anticodón trinucleotídico, en donde el anticodón es 5'-CUA-3' y reconoce codones de paro TAG, y en donde el brazo aceptor está enlazado operativamente a un triptófano, glutamato o glutamina.
MX2020004587A 2017-11-02 2018-11-02 Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt. MX2020004587A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580887P 2017-11-02 2017-11-02
US201862687015P 2018-06-19 2018-06-19
PCT/US2018/059065 WO2019090154A1 (en) 2017-11-02 2018-11-02 Methods of rescuing stop codons via genetic reassignment with ace-trna

Publications (1)

Publication Number Publication Date
MX2020004587A true MX2020004587A (es) 2021-04-12

Family

ID=66332719

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004587A MX2020004587A (es) 2017-11-02 2018-11-02 Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt.
MX2020004647A MX2020004647A (es) 2017-11-02 2018-11-02 Métodos de rescate de codones de detención por medio de reasignación genética con arn de transferencia editado anti-codones (ace-trna).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004647A MX2020004647A (es) 2017-11-02 2018-11-02 Métodos de rescate de codones de detención por medio de reasignación genética con arn de transferencia editado anti-codones (ace-trna).

Country Status (12)

Country Link
US (4) US11661600B2 (es)
EP (2) EP3703762A4 (es)
JP (4) JP7474511B2 (es)
KR (2) KR20200083550A (es)
CN (2) CN111712248A (es)
AU (2) AU2018360055A1 (es)
BR (2) BR112020008725A2 (es)
CA (2) CA3081737A1 (es)
IL (2) IL274356A (es)
MX (2) MX2020004587A (es)
RU (2) RU2020117928A (es)
WO (2) WO2019090154A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712248A (zh) 2017-11-02 2020-09-25 衣阿华大学研究基金会 使用ACE-tRNA经由遗传重分配拯救终止密码子的方法
CA3114108A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
US20230089490A1 (en) * 2019-10-11 2023-03-23 University Of Massachusetts Raav-mediated in vivo delivery of suppressor trnas
WO2021087401A1 (en) * 2019-11-01 2021-05-06 Tevard Bio, Inc. Methods and compositions for treating a premature termination codon-mediated disorder
WO2021113218A1 (en) * 2019-12-02 2021-06-10 Shape Therapeutics Inc. Targeted transfer rnas for treatment of diseases
IL297243A (en) * 2020-04-14 2022-12-01 Flagship Pioneering Innovations Vi Llc trem compositions and their uses
AU2021289600A1 (en) 2020-06-12 2023-01-19 University Of Rochester Encoding and expression of ACE-tRNAs
JP2024502044A (ja) * 2020-12-31 2024-01-17 ユニバーシティー オブ アイオワ リサーチ ファンデーション センス・サプレッサートランスファーrna組成物ならびに関連する用途及び機能
IL305421A (en) * 2021-02-25 2023-10-01 Riboz Llc Engineered expression vectors for increasing synthetic mRNA expression
JP2024517809A (ja) * 2021-05-05 2024-04-23 テバード バイオサイエンシズ インコーポレイテッド 未成熟終止コドン媒介障害を処置するための方法および組成物
CN113308463A (zh) * 2021-05-12 2021-08-27 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 经过反密码子编辑的tRNA作为分子开关在精准控制蛋白表达及病毒复制中的应用
WO2023122785A1 (en) * 2021-12-23 2023-06-29 Shape Therapeutics Inc. Compositions and methods of trna silencing
WO2023141261A1 (en) 2022-01-21 2023-07-27 Hc Bioscience, Inc. Modified transfer rna with improved activity
WO2023147348A1 (en) * 2022-01-25 2023-08-03 Hc Bioscience, Inc. Universal suppressor trnas and uses thereof
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
CN114717204B (zh) * 2022-03-08 2023-12-26 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 复制缺陷型伪狂犬病病毒及其构建方法和应用
WO2023205606A1 (en) 2022-04-18 2023-10-26 Vertex Pharmaceuticals Incorporated Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver
WO2023220083A1 (en) * 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220342A2 (en) * 2022-05-13 2023-11-16 Shape Therapeutics Inc. Engineered tranfer rnas

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
EP1045902B1 (en) 1998-01-14 2005-07-06 Human Gene Therapy Research Institute HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDES AND METHODS OF USE FOR SAME
IL159311A0 (en) 2001-06-13 2004-06-01 Remedies for diseases caused by nonsense mutation
US6964859B2 (en) 2001-10-16 2005-11-15 Massachusetts Institute Of Technology Suppressor tRNA system
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
GB0600948D0 (en) 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
FR2902439A1 (fr) 2006-06-14 2007-12-21 Univ Rene Descartes Paris V Et Arn de transfert chimerique et son utilisation pour la production d'arn par une cellule
WO2009086497A2 (en) 2007-12-28 2009-07-09 Ardell David H Genetic encryption
US20120077186A1 (en) 2010-05-07 2012-03-29 Oregon Health & Science University Use of cysteine-derived suppressor trnas for non-native amino acid incorporation
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
HRP20170589T2 (hr) 2014-12-22 2023-05-12 Sandoz Ag Varijante sekvenci
CN107614689A (zh) 2015-03-27 2018-01-19 昆士兰大学 用于将非天然氨基酸并入蛋白质中的平台
WO2017049409A1 (en) 2015-09-25 2017-03-30 The Centre For Drug Research And Development Compositions for promoting readthrough of premature termination codons, and methods of using the same
CN107177592B (zh) 2016-03-10 2021-03-30 北京大学 抑制性tRNA通读提前终止密码子疾病中的截短蛋白
BR112018073671A2 (pt) 2016-05-16 2019-02-26 The Board Of Regents Of The University Of Texas System composições para a entrega de rnat como nanopartículas e métodos de uso
WO2018031531A1 (en) 2016-08-08 2018-02-15 President And Fellows Of Harvard College Engineered bacteria for non-invasive imaging and therapeutic applications
EP3589751A4 (en) 2017-03-03 2021-11-17 The Regents of The University of California RNA TARGETING OF MUTATIONS VIA SUPPRESSOR RNA AND DEAMINASES
CN111712248A (zh) 2017-11-02 2020-09-25 衣阿华大学研究基金会 使用ACE-tRNA经由遗传重分配拯救终止密码子的方法
WO2019175316A1 (en) 2018-03-15 2019-09-19 Universität Hamburg Synthetic transfer rna with extended anticodon loop
CA3114108A1 (en) 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
US10905778B2 (en) 2018-09-26 2021-02-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
EP3953469A1 (en) 2019-04-11 2022-02-16 Arcturus Therapeutics, Inc. Synthetic transfer rna with extended anticodon loop
US20230089490A1 (en) 2019-10-11 2023-03-23 University Of Massachusetts Raav-mediated in vivo delivery of suppressor trnas
WO2021087401A1 (en) 2019-11-01 2021-05-06 Tevard Bio, Inc. Methods and compositions for treating a premature termination codon-mediated disorder
AU2020379762A1 (en) 2019-11-04 2022-05-26 Flagship Pioneering, Inc. TREM compositions for con-rare codons and related uses
WO2021113218A1 (en) 2019-12-02 2021-06-10 Shape Therapeutics Inc. Targeted transfer rnas for treatment of diseases

Also Published As

Publication number Publication date
RU2020117787A (ru) 2021-12-02
AU2018360065A1 (en) 2020-06-18
CA3081692A1 (en) 2019-05-09
WO2019090169A1 (en) 2019-05-09
CN111818945A (zh) 2020-10-23
JP2021502078A (ja) 2021-01-28
EP3703701A4 (en) 2022-02-09
KR20200083550A (ko) 2020-07-08
US11661600B2 (en) 2023-05-30
IL274356A (en) 2020-06-30
JP2021508234A (ja) 2021-03-04
US20230203482A1 (en) 2023-06-29
JP2024054361A (ja) 2024-04-16
JP2023106545A (ja) 2023-08-01
CN111712248A (zh) 2020-09-25
EP3703762A1 (en) 2020-09-09
JP7474532B2 (ja) 2024-04-25
KR20200090171A (ko) 2020-07-28
WO2019090154A1 (en) 2019-05-09
EP3703701A1 (en) 2020-09-09
MX2020004647A (es) 2021-03-25
JP7474511B2 (ja) 2024-04-25
US20230407300A1 (en) 2023-12-21
IL274396A (en) 2020-06-30
EP3703762A4 (en) 2021-08-18
BR112020008733A2 (pt) 2020-11-03
CA3081737A1 (en) 2019-05-09
US20240182891A1 (en) 2024-06-06
BR112020008725A2 (pt) 2021-03-30
RU2020117928A (ru) 2021-12-03
RU2020117928A3 (es) 2022-05-06
AU2018360055A1 (en) 2020-06-04
US20200291401A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MX2020004587A (es) Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt.
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2021011031A (es) Proceso de transcripción in vitro en lotes alimentados.
WO2019135816A3 (en) Novel nucleic acid modifiers
ES2688623T3 (es) Proteínas de fusión que se unen a factores de crecimiento
EP1735465A4 (en) COMPOSITIONS FOR USE IN THE DETERMINATION OF HEMORRHAGIC FEVERVIRUSES
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
MX2018008135A (es) Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas.
EA201000427A1 (ru) Секвенирование нуклеиново-кислотных полимеров с использованием электронной микроскопии
FR2981088B1 (fr) Arn polymerases mutees
PE20081723A1 (es) Vacuna contra el papilomavirus
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
BR112014021993A2 (pt) detecção da variação de nucleotídeo em sequência de ácido nucleico alvo através de ensaio de clivagem e extensão de pto
AU2017270377A1 (en) Tagged Multi-Nucleotides useful for Nucleic Acid sequencing
WO2016130628A8 (en) Griffithsin mutants
HK1146299A1 (en) Promoter for introducing gene into lymphocyte or blood cell and application thereof
UA92606C2 (ru) Внутриматочная система, которую обнаруживают с помощью ультразвука, и способ улучшения ультразвукового выявления
TR201820975A2 (tr) İbuprofen, Psödoefedrin ve Erdostein İçeren Uzatılmış Salım Sağlayan Farmasötik Kompozisyon
BRPI0510385A (pt) vetores virais polivalentes e um sistema para produção destes
ES2493915T3 (es) Método de detección de microorganismos
RU2018117175A (ru) Рекомбинантный микроорганизм для получения L-треонина и способ получения L-треонина с использованием указанного микроорганизма
WO2019012481A3 (en) G-QUADRUPLEXES DIVIDED FOR CAPTURE AND DETECTION OF NUCLEIC ACIDS
PL403939A1 (pl) Aptamery DNA rozpoznające metkę histydynową oraz ich zastosowanie
HRP20070011A2 (en) Methods and assays for detecting guanylate cyclase activity
PL408735A1 (pl) Aptamer DNA rozpoznający metkę argininową oraz jego zastosowanie